CA2035384A1 - Preparation and use of gene banks of synthetic human antibodies ("synthetic human-antibody libraries") - Google Patents

Preparation and use of gene banks of synthetic human antibodies ("synthetic human-antibody libraries")

Info

Publication number
CA2035384A1
CA2035384A1 CA002035384A CA2035384A CA2035384A1 CA 2035384 A1 CA2035384 A1 CA 2035384A1 CA 002035384 A CA002035384 A CA 002035384A CA 2035384 A CA2035384 A CA 2035384A CA 2035384 A1 CA2035384 A1 CA 2035384A1
Authority
CA
Canada
Prior art keywords
huab
synthetic human
synthetic
preparation
gene banks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002035384A
Other languages
French (fr)
Other versions
CA2035384C (en
Inventor
Melvyn Little
Frank Berthold Breitling
Thomas Seehaus
Stefan Dubel
Iris Klewinghaus
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Siemens Healthcare Diagnostics Products GmbH
Original Assignee
Behringwerke AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Behringwerke AG filed Critical Behringwerke AG
Publication of CA2035384A1 publication Critical patent/CA2035384A1/en
Application granted granted Critical
Publication of CA2035384C publication Critical patent/CA2035384C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1093—General methods of preparing gene libraries, not provided for in other subgroups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/033—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the internal surface of the plasma membrane, e.g. containing a myristoylation motif

Abstract

The invention relates to the preparation and use of gene banks of synthetic human antibodies (huAb) or parts of antibodies which contain the antigen-binding domain.
Starting from a huAb framework in a suitable vector, the hypervariable regions of the antibody cDNA are formed by almost "randomly" combined oligonucleotides. Relatively conserved amino acids in the hypervariable regions have here been taken account of in the choice of appropriate nucleotides during the oligonucleotide synthesis and the ratio of the nucleotides used is likewise chosen such that a nonsense codon is to be expected at most in every 89th position. Expression of this synthetic huAb cDNA in microbial expression systems, e.g. in E, coli in the vector pFMT which is described below, thus makes a synthetic huAb library with a comprehensive repertoire for screening using selected antigens available in vitro.
CA002035384A 1990-02-01 1991-01-31 Preparation and use of gene banks of synthetic human antibodies ("synthetic human-antibody libraries") Expired - Lifetime CA2035384C (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE4002897A DE4002897A1 (en) 1990-02-01 1990-02-01 Synthetic human antibody library
DEP4002897.6 1990-02-01
DE4003880A DE4003880A1 (en) 1990-02-01 1990-02-09 Synthetic human antibody library
DEP4003880.7 1990-02-09

Publications (2)

Publication Number Publication Date
CA2035384A1 true CA2035384A1 (en) 1991-08-02
CA2035384C CA2035384C (en) 2003-07-08

Family

ID=25889601

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002035384A Expired - Lifetime CA2035384C (en) 1990-02-01 1991-01-31 Preparation and use of gene banks of synthetic human antibodies ("synthetic human-antibody libraries")

Country Status (13)

Country Link
US (1) US5840479A (en)
EP (1) EP0440146B1 (en)
JP (1) JPH04211395A (en)
KR (1) KR100221897B1 (en)
AT (1) ATE145427T1 (en)
AU (1) AU638535B2 (en)
CA (1) CA2035384C (en)
DE (3) DE4002897A1 (en)
DK (1) DK0440146T3 (en)
ES (1) ES2097157T3 (en)
GR (1) GR3022131T3 (en)
IE (1) IE75220B1 (en)
PT (1) PT96624B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5316922A (en) * 1992-04-15 1994-05-31 The United States Of America As Represented By Department Of Health And Human Services Method for indentifying and expressing proteins that recognize and adhere to specific probes
US5876961A (en) * 1991-07-15 1999-03-02 Glaxo Wellcome Inc. Production of antibodies

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7063943B1 (en) 1990-07-10 2006-06-20 Cambridge Antibody Technology Methods for producing members of specific binding pairs
US6916605B1 (en) * 1990-07-10 2005-07-12 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) * 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
PT1696031E (en) * 1991-12-02 2010-06-25 Medical Res Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
US20010053523A1 (en) * 1995-06-02 2001-12-20 M&E Biotech A/S. Method for identification of biologically active peptides and nucleic acids
WO1996038553A1 (en) * 1995-06-02 1996-12-05 M&E Biotech A/S A method for identification of biologically active peptides and nucleic acids
US6828422B1 (en) 1995-08-18 2004-12-07 Morphosys Ag Protein/(poly)peptide libraries
DK1143006T3 (en) * 1995-08-18 2008-07-14 Morphosys Ip Gmbh Vectors / DNA sequences from human combinatorial antibody libraries
US6365344B1 (en) * 1996-01-23 2002-04-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for screening for transdominant effector peptides and RNA molecules
US6455247B1 (en) 1996-01-23 2002-09-24 Board Of Trustees Of The Leland Stanford Junior University Methods for screening for transdominant effector peptides and RNA molecules
US7087420B1 (en) 1997-07-17 2006-08-08 Cambia Microbial β-glucuronidase genes, gene products and uses thereof
US6391547B1 (en) * 1997-09-09 2002-05-21 Center For The Application Of Molecular Biology To International Agriculture Microbial β-glucuronidase genes, gene products and uses thereof
US6864235B1 (en) * 1999-04-01 2005-03-08 Eva A. Turley Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
US6911429B2 (en) * 1999-04-01 2005-06-28 Transition Therapeutics Inc. Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
IL130225A0 (en) 1999-05-31 2000-06-01 Yissum Res Dev Co Novel uses of antibodies against ache and peptides thereof
ES2531551T3 (en) * 2000-04-17 2015-03-17 Dyax Corp. Methods for building genetic package presentation libraries for members of a diverse peptide family
US8288322B2 (en) 2000-04-17 2012-10-16 Dyax Corp. Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
US20020110843A1 (en) * 2000-05-12 2002-08-15 Dumas David P. Compositions and methods for epitope mapping
WO2002061071A2 (en) 2000-12-18 2002-08-08 Dyax Corp. Focused libraries of genetic packages
US20040259783A1 (en) * 2001-11-09 2004-12-23 Tony Cruz Pharmaceutical compositions of marine sponge microciona prolifera
DE60232688D1 (en) * 2001-11-20 2009-07-30 Univ Duke BOUNDARY-BIOMATERIALS
KR100528772B1 (en) * 2002-08-02 2005-11-15 주식회사유한양행 A lambda light chain expression vector
KR100604038B1 (en) * 2002-08-02 2006-07-24 주식회사유한양행 A heavy chain expression vector
KR100604037B1 (en) * 2002-08-02 2006-07-24 주식회사유한양행 A kafa light chain expression vector
WO2004013278A2 (en) * 2002-08-02 2004-02-12 Yuhan Corporation Expression vectors
US20040067532A1 (en) 2002-08-12 2004-04-08 Genetastix Corporation High throughput generation and affinity maturation of humanized antibody
CN100406554C (en) * 2003-03-28 2008-07-30 广州医学院 Colibacillus containing human source guide suppository dissolving antibody gene and its secretion producg
ATE462451T1 (en) 2004-06-16 2010-04-15 Affinergy Inc INTERFACE BIOMATERIALS TO PROMOTE ADHESION OF TARGET ANALYTES
US20120208824A1 (en) 2006-01-20 2012-08-16 Cell Signaling Technology, Inc. ROS Kinase in Lung Cancer
EP1973946B1 (en) 2006-01-20 2015-03-25 Cell Signaling Technology, Inc. Translocation and mutant ros kinase in human non-small cell lung carcinoma
WO2007092777A2 (en) * 2006-02-02 2007-08-16 Wyeth Cloning, characterization, and application of tnfrsf19 in neurological disorders
HUE035732T2 (en) 2006-04-14 2018-05-28 Cell Signaling Technology Inc Gene defects and mutant ALK kinase in human solid tumors
US20090252745A1 (en) * 2006-09-15 2009-10-08 Duke University Amino acids in the HCV core polypeptide domain 3 and correlation with steatosis
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
WO2009036379A2 (en) * 2007-09-14 2009-03-19 Adimab, Inc. Rationally designed, synthetic antibody libraries and uses therefor
EP2203558B1 (en) 2007-10-18 2016-05-04 Cell Signaling Technology, Inc. Translocation and mutant ros kinase in human non-small cell lung carcinoma
WO2009114815A1 (en) 2008-03-13 2009-09-17 Dyax Corp Libraries of genetic packages comprising novel hc cdr3 designs
EP2281078B1 (en) * 2008-04-24 2014-10-22 Dyax Corporation Libraries of genetic packages comprising novel hc cdr1, cdr2, and cdr3 and novel lc cdr1, cdr2, and cdr3 designs
CN101768213B (en) 2008-12-30 2012-05-30 中国科学院遗传与发育生物学研究所 Protein related to plant tillering number and coding gene and application thereof
HUE035769T2 (en) 2009-02-12 2018-05-28 Cell Signaling Technology Inc Mutant ROS expression in human liver cancer
CN101817879A (en) 2009-02-26 2010-09-01 中国科学院遗传与发育生物学研究所 Metallothionein and encoding gene and application thereof
DK2435568T3 (en) 2009-05-29 2014-09-08 Morphosys Ag Collection of synthetic antibodies to treat disease
CA2773564A1 (en) * 2009-09-14 2011-03-17 Dyax Corp. Libraries of genetic packages comprising novel hc cdr3 designs
CN102326199B (en) 2009-12-22 2014-11-05 松下电器产业株式会社 Optical disc device, optical disc control method, and integrated circuit
DK3741883T3 (en) 2010-07-16 2023-02-20 Adimab Llc ANTIBODIES LIBRARIES
US20120101108A1 (en) 2010-08-06 2012-04-26 Cell Signaling Technology, Inc. Anaplastic Lymphoma Kinase In Kidney Cancer
ES2696548T3 (en) 2010-11-19 2019-01-16 Morphosys Ag A collection of antibody sequences and their use
HUE037856T2 (en) 2012-04-18 2018-09-28 Cell Signaling Technology Inc Egfr and ros1 in cancer
SG11202001551YA (en) 2017-08-21 2020-03-30 Adagene Inc Dynamic human heavy chain antibody libraries
KR20200054209A (en) 2017-08-21 2020-05-19 아다진 인크. Dynamic human antibody light chain library
US20230303666A1 (en) * 2020-09-24 2023-09-28 The Broad Institute, Inc. Cell-free antibody engineering platform and neutralizing antibodies for sars-cov-2

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE114723T1 (en) * 1987-03-02 1994-12-15 Enzon Lab Inc ORGANISM AS CARRIER FOR ''SINGLE CHAIN ANTIBODY DOMAIN (SCAD)''.

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5876961A (en) * 1991-07-15 1999-03-02 Glaxo Wellcome Inc. Production of antibodies
US5316922A (en) * 1992-04-15 1994-05-31 The United States Of America As Represented By Department Of Health And Human Services Method for indentifying and expressing proteins that recognize and adhere to specific probes

Also Published As

Publication number Publication date
DK0440146T3 (en) 1997-03-10
JPH04211395A (en) 1992-08-03
CA2035384C (en) 2003-07-08
AU638535B2 (en) 1993-07-01
KR910021474A (en) 1991-12-20
DE4002897A1 (en) 1991-08-08
US5840479A (en) 1998-11-24
ES2097157T3 (en) 1997-04-01
EP0440146A2 (en) 1991-08-07
EP0440146A3 (en) 1992-07-15
DE4003880A1 (en) 1991-08-14
AU7011591A (en) 1991-08-08
IE75220B1 (en) 1997-08-27
EP0440146B1 (en) 1996-11-20
PT96624A (en) 1991-11-29
KR100221897B1 (en) 1999-10-01
GR3022131T3 (en) 1997-03-31
ATE145427T1 (en) 1996-12-15
DE59108350D1 (en) 1997-01-02
IE910336A1 (en) 1991-08-14
PT96624B (en) 1998-07-31

Similar Documents

Publication Publication Date Title
CA2035384A1 (en) Preparation and use of gene banks of synthetic human antibodies ("synthetic human-antibody libraries")
Georges et al. Topology of P-glycoprotein as determined by epitope mapping of MRK-16 monoclonal antibody.
AU2009201674B2 (en) Novel anti-IGF-IR antibodies and uses thereof
CN1753912B (en) Antibodies against PD-1 and uses therefor
MY136224A (en) Monkey monoclonal antibodies specific to human b7.1 and/or b7.2,primatized forms thereof,pharmaceutical compos itions containing, and use thereof as immunosuppressants
MX9709778A (en) High affinity human monoclonal antibodies specific for rsv f-protein.
US6790938B1 (en) Anti-GPIIb/IIIa recombinant antibodies
TW438886B (en) Gene encoding human adseverin
AU633682B2 (en) Preparation and use of gene banks of human antibodies ("human-antibody libraries")
WO1997002479A3 (en) Human monoclonal anti-tumor antibodies
HU9503285D0 (en) Anti-egfr single-chain fvs and anti-egfr antibodies
PL193780B1 (en) Novel method for the production of anti-human antigen receptors and uses thereof
EP1555328A3 (en) Recombinant library screening methods
EP2287191A3 (en) Human IGM antibodies with the capability of inducing remyelination, and diagnostic and therapeutic uses thereof particularly in the central nervous system
JP2010222378A (en) Peptide-based passive immunization therapy for treatment of atherosclerosis
CA2012993A1 (en) Monoclonal antibodies (mabs) against tumor-associated antigens, the preparation and use thereof
Dziegiel et al. Phage display used for gene cloning of human recombinant antibody against the erythrocyte surface antigen, rhesus D
EP1491632A3 (en) Anti-alphavbeta3 humanized monoclonal antibodies
Welschof et al. The antigen binding domain of non-idiotypic human anti-F (ab′) 2 autoantibodies: study of their interaction with IgG hinge region epitopes
WO2001051644A3 (en) ANTI-CD3 SINGLE-CHAIN ANTIBODIES HAVING HUMAN Cν3 AND Cν4 DOMAINS
EP0699688A3 (en) Chlamydia pneumoniae specific monoclonal antibodies and their diagnostic use
Lafaye et al. Biologically active human anti-crotoxin scFv isolated from a semi-synthetic phage library
MX9601930A (en) Anti-idiotypic antibodies which induce an immune response against growth factor receptor.
Orlandi et al. Antigenic and immunogenic mimicry of the HER2/neu oncoprotein by phage‐displayed peptides
SCHLEBUSCH et al. Production of a single-chain fragment of the murine anti-idiotypic antibody ACA125 as phage-displayed and soluble antibody by recombinant phage antibody technique

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry